蒿甲醚联合复方磷酸萘酚喹治疗非洲60例恶性疟疾患者的临床效果

doi:10.3969/j.issn.1002-1949.2019.08.012

Chinese Journal of Critical Care Medicine

2019, Vol. 39

Issue (8): 767-770 DOI: 10.3969/j.issn.1002-1949.2019.08.012

Clinical effect of artemether combined with compound naphtholine phosphate in the treatment of 60 patients with falciparum malaria in Africa

Department of Emergency, Tianjin Fifth Central Hospital, Tianjin 300450，China

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (559 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy and safety of artemether combined with compound naphtholine phosphate in the treatment of falciparum malaria in Africa. Methods A total of 119 cases of falciparum malaria admitted from March 2014 to November 2016 and during the assistance of Gabon in Africa were divided into the control group ( n =59) and the observation group ( n =60) according to the treatment scheme. On the basis of the two groups treated by lowering the temperature, anti-infection and other conventional symptomatic support treatment, the control group was treated with artemether, while the observation group was treated with artemether combined with compound naphtholine phosphate. The treatment effect, treatment cycle, switched time of plasmodium, antipyretic time, disappearance time of headache, recurrence rate of the disease, incidence of adverse reactions and levels of blood biochemical parameters ［total red blood cell count (RBC), hemoglobin (Hb), platelet count (PLT)］ before and after treatment were compared between the two groups. Results The therapeutic effect of the observation group was better than that of the control group ( P <0.05). The treatment period, the time of malaria negative transformation, the time of fever abatement and the time of headache disappearance in the observation group were (7.41±1.29) d, (5.21±1.06) d, (4.05±0.84) d, (3.68±0.92) d, respectively, shorter than those in the control group (8.83±1.42) d, (6.95± 1.72 )d, (5.97±0.91) d, (5.63±0.81) d ( P < 0.05). After treatment, the RBC, Hb and PLT levels in the observation group were (4.79±0.68) ×10 12 /L, (146.27±15.30) g/L, (189.53± 28.29 )×10 9/L, respectively, higher than those in the control group ［(4.31±0.64)×10 12 /L, (134.45± 15.96 ) g/L, (165.74±26.05)×10 9/L; P <0.05］. During the treatment period, the incidence of adverse reactions in the observation group was 8.33% compared with 5.08% in the control group, there was no significant difference ( P >0.05); the follow-up showed that the rate of disease relapse in the observation group was 1.85% lower than that in the control group (17.24%, P <0.05). Conclusion Artemether combined with compound naphtholine phosphate and quinine in the treatment of patients with falciparum malaria in Africa can significantly improve the curative effect, improve the levels of blood biochemical indexes such as RBC, Hb and PLT, promote the rehabilitation of the disease, and reduce the relapse rate of the disease. Besides, it has certain safety.

Key words： Falciparum malaria in Africa Artemether Compound naphtholine phosphate Treatment cycle Switched time of plasmodium Recurrence rate of the disease

About author:: Xu Chun-lei, E-mail: E-mail:maple-xcl@sina.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.cnemergency.org.cn/EN/10.3969/j.issn.1002-1949.2019.08.012 OR http://www.cnemergency.org.cn/EN/Y2019/V39/I8/767

［1］Biggs J,Raman J, Cook J, et al. Serology reveals heterogeneity of plasmodium falciparum transmission in northeastern south africa:implications for malaria elimination［J］. Malar J, 2017, 16(1): 48.〖JP〗 ［2］陈世洪,章光华.非洲赤道几内亚恶性疟疾4120例诊治体会［J］. 广东医学, 2014, 35(4):568-570. ［3］Zwang J, D′Alessandro U, Ndiaye JL, et al. Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa［J］. BMC Infect Dis, 2017, 17(1): 443. ［4］单琳琳,尚晓鹏,宋世震,等. 蒿甲醚治疗重症疟疾的Meta分析［J］.中国病原生物学杂志, 2013, 8(7): 611-616. ［5］李兴国,王芳,薛越. 蒿甲醚与青蒿琥酯治疗恶性疟疾疗效对比观察［J］.人民军医, 2013, 56(10): 1143-1144. ［6］王岩,冯国和. 恶性疟疾发病机制及其防治进展［J］.国际流行病学传染病学杂志, 2014, 41(5): 336-341. ［7］陈灏珠,林果为. 实用内科学［M］. 第13版. 北京:人民卫生出版社, 2009: 714. ［8］司慧远,李晓娟,姚宁,等.伯氨喹与蒿甲醚联合治疗恶性疟疾的疗效评价［J］.空军医学杂志, 2015, 31(1):37-39. ［9］段文斌,严志刚,段惠春,等.青蒿琥酯联合蒿甲醚治疗耐药恶性疟疾患者疗效观察［J］.实用肝脏病杂志, 2014,17(6):655-656. ［10］Mobegi VA,Duffy CW,Amambua-Ngwa A,et al.Genome-wide analysis of selection on the malaria parasite plasmodium falciparum in west african populations of differing infection endemicity［J］.Mol Biol Evol, 2014, 31(6):1490-1499. ［11］Eziefula AC, Pett H, Grignard L, et al. Glucose-6-phosphate dehydrogenase status and risk of hemolysis in plasmodium falciparum-infected african children receiving single-dose primaquine［J］. Antimicrob Agents Chemother, 2014, 58(8): 4971-4973. ［12］熊红霞,李新萍,徐友高. 国产双氢青蒿素哌喹片治疗非洲恶性疟疾效果评价［J］. 深圳中西医结合杂志, 2016, 26(11): 54-56. ［13］武新胜,王文锋.青蒿琥酯和青蒿琥酯-盐酸阿莫地喹序贯治疗南苏丹恶性疟疾疗效观察［J］. 新乡医学院学报, 2018, 35(2): 118-121. ［14］罗红敏.双氢青蒿素哌喹与磺胺多辛/乙胺嘧啶的抗疟疾疗效对比［J］.中华危重病急救医学, 2017, 29(8):693. ［15］Bastiaens GJH, Tiono AB, Okebe J,et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males:Two open-label,randomized,safety trials［J］. PloS One, 2018, 13(1): e0 190 272. ［16］张亚红,王丽娟,甘淋玲,等. 蒿甲醚及其制剂的临床应用研究进展［J］. 重庆医学, 2014, 43(29): 3967-3970. ［17］王忠磊,胡颖新,付婷霞,等. 蒿甲醚、青蒿琥酯等抗疟药治疗输入性恶性疟临床观察［J］. 寄生虫病与感染性疾病, 2016, 14(3): 129-132. ［18］Lu F, Culleton R, Zhang M,et al. Emergence of indigenous artemisinin-resistant plasmodium falciparum in africa［J］. N Engl J Med, 2017, 376(10):991-993. ［19］江海龙,卢丽琨,常学辉,等.复方磷酸萘酚喹片治疗非洲恶性疟疾35例［J］.中国热带医学, 2016, 16(2): 195-196. ［20］包芙莉,陈强,张小威,等. 522例刚果(金)维和人员恶性疟患者血细胞与血脂变化分析［J］.国际检验医学杂志, 2018, 39(2):2 35-237. ［21］陈冰,叶兆萍,诸兴桂. 疟疾感染患者全血细胞计数结果变化研究［J］.检验医学与临床, 2016, 13(22): 3257-3258.